Pharyngitis News and Research

RSS
UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Genetic innovations for pneumonia diagnosis in children

Genetic innovations for pneumonia diagnosis in children

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

Study finds dramatic increase in acute throat infection admissions in England

Study finds dramatic increase in acute throat infection admissions in England

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

FDA approves Acton’s AEROSPAN sNDA to treat asthma

FDA approves Acton’s AEROSPAN sNDA to treat asthma

FDA clears Meridian Bioscience’s new illumigene Group A Strep test

FDA clears Meridian Bioscience’s new illumigene Group A Strep test

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Lilly announces final results from ALIMTA Phase III study on NSCLC

Lilly announces final results from ALIMTA Phase III study on NSCLC

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene announces interim results of REVLIMID study on CLL

Celgene announces interim results of REVLIMID study on CLL